The Centers for Medicare & Medicaid Services (CMS) has issued a proposed rule that would update payment policies and rates under the End-Stage Renal Disease (ESRD) Prospective Payment System.
If adopted, the changes would apply to dialysis services rendered from January 1, 2012, forward. Among other suggested revisions, CMS wants to eliminate the “50% rule,” and instead exclude all panel tests from the definition of ESRD outlier services and the outlier computation.
CME also wants to exclude certain thrombolytic agents when computing whether a facility is entitled to outlier payments, but include in the computation testosterone, anabolic steroids, and certain drugs used for anemia management.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.